A krónikus myeloid leukaemia korszerũ diagnosztikája és kezelése

Translated title of the contribution: Chronic myelogenous leukemia: Diagnosis and treatment

J. Demeter, Anna Poros, Csaba Bödör, Laura Horváth, T. Masszi

Research output: Contribution to journalReview article

1 Citation (Scopus)

Abstract

Chronic myelogenous leukemia is a clonal myeloproliferative neoplasm caused by reciprocal translocation involving chromosomes 9 and 22 resulting in the expression of a constitutively activated BCR-ABL1 tyrosine kinase that leads to the malignant transformation of the hematopoietic stem cells. The condition was previously known as a relentlessly progressive disease, but the treatment was revolutionalized by the efficacy of tyrosine kinase inhibitors. Therapeutic success is thus currently determined by the depth of molecular response achieved on therapy. Multiple tyrosine kinase agents are available even for the first line treatment. This guideline summarizes current focal points of the treatment of chronic myelogenous leukemia specific to Hungary and provides definitions for optimal molecular responses in this condition.

Original languageHungarian
Pages (from-to)1459-1468
Number of pages10
JournalOrvosi Hetilap
Volume157
Issue number37
DOIs
Publication statusPublished - Sep 1 2016

Fingerprint

Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Protein-Tyrosine Kinases
Chromosomes, Human, Pair 22
Chromosomes, Human, Pair 9
Hungary
Hematopoietic Stem Cells
Guidelines
Therapeutics
Neoplasms

ASJC Scopus subject areas

  • Medicine(all)

Cite this

A krónikus myeloid leukaemia korszerũ diagnosztikája és kezelése. / Demeter, J.; Poros, Anna; Bödör, Csaba; Horváth, Laura; Masszi, T.

In: Orvosi Hetilap, Vol. 157, No. 37, 01.09.2016, p. 1459-1468.

Research output: Contribution to journalReview article

Demeter, J. ; Poros, Anna ; Bödör, Csaba ; Horváth, Laura ; Masszi, T. / A krónikus myeloid leukaemia korszerũ diagnosztikája és kezelése. In: Orvosi Hetilap. 2016 ; Vol. 157, No. 37. pp. 1459-1468.
@article{d0f5e1fe7e1b4286b3fd2df85f35701f,
title = "A kr{\'o}nikus myeloid leukaemia korszerũ diagnosztik{\'a}ja {\'e}s kezel{\'e}se",
abstract = "Chronic myelogenous leukemia is a clonal myeloproliferative neoplasm caused by reciprocal translocation involving chromosomes 9 and 22 resulting in the expression of a constitutively activated BCR-ABL1 tyrosine kinase that leads to the malignant transformation of the hematopoietic stem cells. The condition was previously known as a relentlessly progressive disease, but the treatment was revolutionalized by the efficacy of tyrosine kinase inhibitors. Therapeutic success is thus currently determined by the depth of molecular response achieved on therapy. Multiple tyrosine kinase agents are available even for the first line treatment. This guideline summarizes current focal points of the treatment of chronic myelogenous leukemia specific to Hungary and provides definitions for optimal molecular responses in this condition.",
keywords = "BCR-ABL tyrosine kinase, Chronic myelogenous leukemia, Hungary, Practice guideline",
author = "J. Demeter and Anna Poros and Csaba B{\"o}d{\"o}r and Laura Horv{\'a}th and T. Masszi",
year = "2016",
month = "9",
day = "1",
doi = "10.1556/650.2016.30521",
language = "Hungarian",
volume = "157",
pages = "1459--1468",
journal = "Orvosi Hetilap",
issn = "0030-6002",
publisher = "Akademiai Kiado",
number = "37",

}

TY - JOUR

T1 - A krónikus myeloid leukaemia korszerũ diagnosztikája és kezelése

AU - Demeter, J.

AU - Poros, Anna

AU - Bödör, Csaba

AU - Horváth, Laura

AU - Masszi, T.

PY - 2016/9/1

Y1 - 2016/9/1

N2 - Chronic myelogenous leukemia is a clonal myeloproliferative neoplasm caused by reciprocal translocation involving chromosomes 9 and 22 resulting in the expression of a constitutively activated BCR-ABL1 tyrosine kinase that leads to the malignant transformation of the hematopoietic stem cells. The condition was previously known as a relentlessly progressive disease, but the treatment was revolutionalized by the efficacy of tyrosine kinase inhibitors. Therapeutic success is thus currently determined by the depth of molecular response achieved on therapy. Multiple tyrosine kinase agents are available even for the first line treatment. This guideline summarizes current focal points of the treatment of chronic myelogenous leukemia specific to Hungary and provides definitions for optimal molecular responses in this condition.

AB - Chronic myelogenous leukemia is a clonal myeloproliferative neoplasm caused by reciprocal translocation involving chromosomes 9 and 22 resulting in the expression of a constitutively activated BCR-ABL1 tyrosine kinase that leads to the malignant transformation of the hematopoietic stem cells. The condition was previously known as a relentlessly progressive disease, but the treatment was revolutionalized by the efficacy of tyrosine kinase inhibitors. Therapeutic success is thus currently determined by the depth of molecular response achieved on therapy. Multiple tyrosine kinase agents are available even for the first line treatment. This guideline summarizes current focal points of the treatment of chronic myelogenous leukemia specific to Hungary and provides definitions for optimal molecular responses in this condition.

KW - BCR-ABL tyrosine kinase

KW - Chronic myelogenous leukemia

KW - Hungary

KW - Practice guideline

UR - http://www.scopus.com/inward/record.url?scp=84987681421&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84987681421&partnerID=8YFLogxK

U2 - 10.1556/650.2016.30521

DO - 10.1556/650.2016.30521

M3 - Review article

C2 - 27615196

AN - SCOPUS:84987681421

VL - 157

SP - 1459

EP - 1468

JO - Orvosi Hetilap

JF - Orvosi Hetilap

SN - 0030-6002

IS - 37

ER -